West Lebanon, NH, United States of America

Elizabeth Nowak

This inventor holds 18 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Autoimmune Disorder Treatment. Top assignees: Dartmouth College, Io Therapeutics, Inc., King's College London. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elizabeth Nowak. Retrieved from https://idiyas.com/inventor/elizabeth-nowak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 16(Granted Patents)

Company Filing History:

Io Therapeutics, Inc.

patents

6 out of 196

King's College London

patents

4. 1 out of 3

Lo Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

Areas of Expertise:

Autoimmune Disorders

RXR Agonists

VISTA-Ig

Immunomodulatory Effects

Remyelination

VISTA Antagonist

Treatment Methods

Inflammatory Disorders

Allergic Disorders

Disease Treatment

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383521 - Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists (2025-08-12),

2. 12162928 - VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders (2024-12-10),

3. 12071473 - VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders (2024-08-27),

4. 12064463 - Vista antagonist and methods of use (2024-08-20),

5. 11793781 - Autoimmune disorder treatment using RXR agonists (2023-10-24),

6. 11752189 - Vista antagonist and methods of use (2023-09-12),

7. 11576881 - Autoimmune disorder treatment using RXR agonists (2023-02-14),

8. 11547684 - Autoimmune disorder treatment using RXR agonists (2023-01-10),

9. 11246845 - Autoimmune disorder treatment using RXR agonists (2022-02-15),

10. 11166927 - Autoimmune disorder treatment using RXR agonists (2021-11-09),

11. 10945976 - Autoimmune disorder treatment using RXR agonists (2021-03-16),

12. 10933115 - VISTA antagonist and methods of use (2021-03-02),

13. 10745467 - VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders (2020-08-18),

14. 10695307 - Autoimmune disorder treatment using RXR agonists (2020-06-30),

15. 10653650 - Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists (2020-05-19),

Sure, here is the article about inventor Elizabeth Nowak:

Title: Innovator Spotlight: Elizabeth Nowak - Pioneering Advances in Autoimmune Treatment

Introduction:

Elizabeth Nowak, a prolific inventor based in West Lebanon, NH (US), is making waves in the medical field with her groundbreaking contributions to the treatment of autoimmune, allergic, and inflammatory disorders. With an impressive portfolio of 16 patents to her name, Nowak's innovative approach is revolutionizing the way we address these challenging health conditions.

Latest Patents:

Nowak's latest patents include the revolutionary VISTA-Ig fusion protein, designed to target regulatory T cell protein VISTA (V-domain Immunoglobulin Suppressor of T cell Activation) for the treatment of autoimmune diseases, allergies, and inflammatory conditions. Additionally, her work on VISTA antagonists opens up new possibilities for combating cancer, infections, and other diseases at a molecular level.

Career Highlights:

Having worked with esteemed institutions such as Dartmouth College and Io Therapeutics, Inc., Nowak has honed her skills and expertise in the field of biomedical research. Her relentless pursuit of innovative solutions has led to her impressive patent portfolio and cemented her reputation as a leading figure in the medical innovation space.

Collaborations:

Throughout her career, Nowak has collaborated closely with esteemed colleagues such as Randolph J Noelle and Roshantha A Chandraratna. Together, they have unlocked new possibilities in the realm of autoimmune treatment and paved the way for future advancements in the field.

Conclusion:

In conclusion, Elizabeth Nowak's groundbreaking work in developing novel therapies for autoimmune disorders underscores her unwavering commitment to improving patient outcomes and advancing medical science. Her innovative spirit and collaborative approach continue to inspire and shape the future of healthcare innovation.

Profile summary based on public USPTO records.